(Q27027040)

title

Early pulmonary inflammation and lung damage in children with cystic fibrosis (English)

0 references

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25823858%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Stephen M. Stick

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25823858%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

André Schultz

series ordinal

1

1 reference

Stephen Stick

series ordinal

2

1 reference

language of work or name

1 reference

May 2015

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25823858%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

20

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25823858%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

4

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25823858%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

569-578

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25823858%20AND%20SRC:MED&resulttype=core&format=json

Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Progression of early structural lung disease in young children with cystic fibrosis assessed using CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Infection, inflammation, and lung function decline in infants with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Changes in airway dimensions on computed tomography scans of children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Scoring of chest CT in children with cystic fibrosis: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

CFTR: a hub for kinases and crosstalk of cAMP and Ca2+

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Interaction between calcium-activated chloride channels and the cystic fibrosis transmembrane conductance regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Regulation of the epithelial sodium channel by serine proteases in human airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Sodium channels and cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Regulation of the epithelial Na+ channel and airway surface liquid volume by serine proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Antimicrobial activity of PLUNC protects against Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

SPLUNC1/BPIFA1 contributes to pulmonary host defense against Klebsiella pneumoniae respiratory infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Unfolding dynamics of the mucin SEA domain probed by force spectroscopy suggest that it acts as a cell-protective device

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Mucus clearance, MyD88-dependent and MyD88-independent immunity modulate lung susceptibility to spontaneous bacterial infection and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Calcium and pH-dependent packing and release of the gel-forming MUC2 mucin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Inhibition of airway proteases in cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Pulmonary surfactant, lung function, and endobronchial inflammation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Sterile inflammation: sensing and reacting to damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Spectrum of viral infections in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

High rhinovirus burden in lower airways of children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Airway epithelial cells, cytokines, and pollutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

The airway epithelium: soldier in the fight against respiratory viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Innate inflammatory responses of pediatric cystic fibrosis airway epithelial cells: effects of nonviral and viral stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Lower airway inflammation in infants with cystic fibrosis detected by newborn screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Toll-like receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

CFTR is a negative regulator of NFkappaB mediated innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

ER-associated complexes (ERACs) containing aggregated cystic fibrosis transmembrane conductance regulator (CFTR) are degraded by autophagy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

DeltaF508-CFTR causes constitutive NF-kappaB activation through an ER-overload response in cystic fibrosis lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Atypical activation of the unfolded protein response in cystic fibrosis airway cells contributes to p38 MAPK-mediated innate immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Rescue of dysfunctional autophagy attenuates hyperinflammatory responses from cystic fibrosis cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Modifying disease in cystic fibrosis: current and future therapies on the horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis andCFTRStop Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Oral steroids for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Ibuprofen therapy for cystic fibrosis lung disease: revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Mechanisms of action and clinical application of macrolides as immunomodulatory medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis L

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

New pulmonary therapies directed at targets other than CFTR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. A pilot study using inhaled hypertonic saline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Dornase alfa for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Early intervention studies in infants and preschool children with cystic fibrosis: are we ready?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Risk Factors for Bronchiectasis in Children with Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521

Multicenter Randomized Controlled Trial of Withdrawal of Inhaled Corticosteroids in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FRESP.12521